JP2020525498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020525498A5 JP2020525498A5 JP2019572377A JP2019572377A JP2020525498A5 JP 2020525498 A5 JP2020525498 A5 JP 2020525498A5 JP 2019572377 A JP2019572377 A JP 2019572377A JP 2019572377 A JP2019572377 A JP 2019572377A JP 2020525498 A5 JP2020525498 A5 JP 2020525498A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- use according
- per year
- seq
- fix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762526377P | 2017-06-29 | 2017-06-29 | |
| US62/526,377 | 2017-06-29 | ||
| PCT/EP2018/067523 WO2019002532A1 (en) | 2017-06-29 | 2018-06-29 | 21-DAY FUSION PROTEIN DRAFTING COMPRISING IX FACTOR AND HUMAN ALBUMIN FOR THE PROPHYLACTIC TREATMENT OF HEMOPHILIA AND ASSOCIATED METHODS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020525498A JP2020525498A (ja) | 2020-08-27 |
| JP2020525498A5 true JP2020525498A5 (https=) | 2021-07-26 |
Family
ID=62815032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572377A Pending JP2020525498A (ja) | 2017-06-29 | 2018-06-29 | 血友病の予防的処置のための第ｉｘ因子およびヒトアルブミンを含む融合タンパク質に関する２１日の投与計画およびその方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200115436A1 (https=) |
| EP (1) | EP3645034B1 (https=) |
| JP (1) | JP2020525498A (https=) |
| KR (1) | KR102597725B1 (https=) |
| CN (1) | CN110799209A (https=) |
| AU (1) | AU2018294517B2 (https=) |
| CA (1) | CA3068360A1 (https=) |
| DK (1) | DK3645034T5 (https=) |
| ES (1) | ES2963665T3 (https=) |
| IL (1) | IL271160B2 (https=) |
| MX (1) | MX2019014651A (https=) |
| PL (1) | PL3645034T3 (https=) |
| RU (1) | RU2020103424A (https=) |
| SG (1) | SG10202111032PA (https=) |
| WO (1) | WO2019002532A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
| KR20120061898A (ko) * | 2009-08-20 | 2012-06-13 | 체에스엘 베링 게엠베하 | 출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자 |
| UA126265C2 (uk) | 2010-07-09 | 2022-09-14 | Байовератів Терапьютікс Інк. | Поліпептид фактора іх і спосіб його застосування |
| TWI750197B (zh) * | 2012-09-25 | 2021-12-21 | 美商百歐維拉提夫治療公司 | Ｆｉｘ多肽的應用 |
| BR112016013577A2 (pt) * | 2013-12-23 | 2017-10-03 | Csl Ltd | Proteínas de fusão, seu uso e composição farmacêutica |
| WO2015154139A1 (en) * | 2014-04-11 | 2015-10-15 | Csl Limited | Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor |
-
2018
- 2018-06-29 IL IL271160A patent/IL271160B2/en unknown
- 2018-06-29 JP JP2019572377A patent/JP2020525498A/ja active Pending
- 2018-06-29 AU AU2018294517A patent/AU2018294517B2/en active Active
- 2018-06-29 MX MX2019014651A patent/MX2019014651A/es unknown
- 2018-06-29 CA CA3068360A patent/CA3068360A1/en active Pending
- 2018-06-29 DK DK18736860.0T patent/DK3645034T5/da active
- 2018-06-29 PL PL18736860.0T patent/PL3645034T3/pl unknown
- 2018-06-29 ES ES18736860T patent/ES2963665T3/es active Active
- 2018-06-29 SG SG10202111032PA patent/SG10202111032PA/en unknown
- 2018-06-29 CN CN201880042643.9A patent/CN110799209A/zh active Pending
- 2018-06-29 RU RU2020103424A patent/RU2020103424A/ru unknown
- 2018-06-29 US US16/626,153 patent/US20200115436A1/en not_active Abandoned
- 2018-06-29 WO PCT/EP2018/067523 patent/WO2019002532A1/en not_active Ceased
- 2018-06-29 EP EP18736860.0A patent/EP3645034B1/en active Active
- 2018-06-29 KR KR1020207002673A patent/KR102597725B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mannucci | Hemophilia treatment innovation: 50 years of progress and more to come | |
| EP2125004B1 (en) | Synergistic therapeutic use of prothrombin complex concentrates with fviii concentrates | |
| ES2392569T3 (es) | Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias | |
| TWI690325B (zh) | 因子viii多肽調配物 | |
| JP2018522563A5 (https=) | ||
| ES2349024T3 (es) | Metodo para aumentar la recuperacion in vivo de polipeptidos terapeuticos. | |
| JP2016516722A5 (https=) | ||
| JP2017521074A5 (https=) | ||
| RU2016129911A (ru) | Слитые белки, содержащие фактор ix, для профилактического лечения больных гемофилией и способы его осуществления | |
| Hogan et al. | α1-Antitrypsin: key player or bystander in acute respiratory distress syndrome? | |
| JP7236446B2 (ja) | コア－シェル構造のマイクロ粒子を有効成分として含む血液凝固因子遺伝子発現増加用組成物 | |
| JP2020525498A5 (https=) | ||
| Ragni | Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy | |
| Schulte | Challenges for new haemophilia products from a manufacturer’s perspective | |
| JP2017508806A5 (https=) | ||
| US11554156B2 (en) | Pharmaceutical formulations of C1 esterase inhibitor | |
| JP2019524089A5 (https=) | ||
| Escobar | Treatment on demand–in vivo dose finding studies | |
| Goubran et al. | New monoclonal/bi-specific antibodies: reshaping transfusion medicine beyond replacement | |
| RU2020103424A (ru) | Схема введения с 21-дневными интервалами слитых белков, содержащих фактор ix и альбумин человека, для профилактического лечения гемофилии и способы такого лечения | |
| Leon et al. | The Role of Selected Adjuncts in the Management of the Bleeding Trauma Patient: Calcium and Vasopressin | |
| US10596232B2 (en) | Methods and compositions related to long half-life coagulation complexes | |
| JP2017513831A (ja) | 出血の予防および処置のための半減期延長型（ｈａｌｆ−ｌｉｆｅ ｅｘｔｅｎｄｅｄ）第ｆｖｉｉａ因子タンパク質、ならびに、その投与レジメン | |
| Duan et al. | Promising coagulation factor VIII bypassing strategies for patients with haemophilia A | |
| Тарасова | Innonafactor: The first Russian recombinant factor IX |